Corventum
1 known investors
Corventum is a biopharmaceutical company developing therapies that protect the heart from the toxic effects of cancer treatment, allowing patients to continue first-line oncology therapy. Its lead program, CVT-130, is a small molecule for the prevention of anthracycline cardiotoxicity, advancing into the clinic in 2026.
Also known as Corventum Inc. · Corventum, Inc.
Investors · 1
Company profile
researched Aug 2026Corventum, Inc. is a biopharmaceutical company developing therapies intended to make existing cancer treatments safer and more effective, beginning with drugs that protect the heart from the toxic effects of cancer therapy so that patients can continue first-line oncology treatment without interruption. The company frames its approach as an alternative to developing increasingly complex and expensive biologics for small patient cohorts, with the aim of affecting a larger number of patients sooner.
Its lead program, CVT-130, is a small molecule described as a first-in-class metabolic modulator designed to prevent anthracycline-related cardiac injury and to address additional diseases involving mitochondrial dysfunction. According to the company, preclinical data show cardioprotection without loss of anthracycline anti-tumor potency. CVT-130 is formulated to be room-temperature stable and administered by rapid injection prior to anthracycline chemotherapy. The company received FDA clearance of the Investigational New Drug application for CVT-130 in October 2025 and plans a randomized, placebo-controlled first-in-human Phase 1 trial in healthy volunteers in the second quarter of 2026, evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, and cardiac and mitochondrial biomarkers, with the goal of selecting a dose for a subsequent Phase 2 trial in cancer patients.
Founding story
Corventum was co-founded by Randall Peterson, Ph.D., Dean of the University of Utah College of Pharmacy, and Aarti Asnani, M.D., Chair of the Cardio-Oncology Committee of the American Heart Association. Both are co-inventors of CVT-130.
Business model
Corventum develops proprietary small-molecule drug candidates in-house, advancing them through preclinical and clinical development toward regulatory approval.
Traction
FDA cleared the IND application for CVT-130 in October 2025, following preclinical work; the company aligned the Phase 1 study design with the FDA and plans trial initiation in the second quarter of 2026.
Latest developments
On October 13-15, 2025, Corventum announced FDA clearance of the IND application for CVT-130 for prevention of anthracycline-related cardiotoxicity, with a randomized, placebo-controlled Phase 1 trial in healthy volunteers planned for the second quarter of 2026.
▸Full profile — market position, technology, go-to-market, geography
Market position
Corventum is targeting cardioprotection during anthracycline chemotherapy, a setting in which anthracyclines are used in more than two million patients per year but whose clinical utility is limited by cumulative, dose-dependent cardiac damage that can lead to heart failure and reduced long-term survival. The company describes CVT-130 as first-in-class and states that no existing therapy has combined cardiac protection with preserved anti-tumor potency.
The company positions CVT-130 as preventing cardiac injury while maintaining full anthracycline anti-tumor activity, a combination it states no prior therapy has achieved, alongside a room-temperature stable formulation permitting rapid pre-chemotherapy injection.
Technology
CVT-130 is a small-molecule metabolic modulator that acts on mitochondrial and metabolic pathways to prevent anthracycline-induced cardiac injury and preserve mitochondrial function. The company reports preclinical cardioprotection with no loss of anthracycline efficacy, and the candidate has a room-temperature stable formulation intended for rapid injection immediately before anthracycline chemotherapy. The mechanism is also positioned for potential application in other conditions involving mitochondrial dysfunction.
Go-to-market
Cancer patients receiving anthracycline chemotherapies such as doxorubicin, epirubicin, and daunorubicin, including patients who have reached lifetime anthracycline dose limits and would otherwise be unable to be retreated for recurrent disease. The company also cites payers and providers as stakeholders benefiting from safer use of existing cancer therapies.
Geography
Announcements are datelined Boston, Massachusetts and Salt Lake City, Utah, with the lead program's development tied to the U.S. regulatory pathway (FDA).
Compiled by commissioned research from 6 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 1
launches, deals, and filingsCorventum announced U.S. FDA clearance of the Investigational New Drug application for CVT-130, a first-in-class small-molecule metabolic modulator for the prevention of anthracycline-related cardiotoxicity. The company said it worked with the FDA to align on the Phase 1 study design.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 6
primary sources listed
- Corventumcorventum.com · web
6 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Corventum do?
- Corventum is a clinical-stage biopharmaceutical company developing CVT-130 to prevent anthracycline-induced cardiotoxicity.
- Who are Corventum's investors?
- Corventum's investors include Utah Innovation Fund.